サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654632

心房細動の世界市場：2025年～2033年

Global Atrial Fibrillation Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
心房細動の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心房細動の世界市場は2024年に267億5,000万米ドルに達し、2033年までには637億9,000万米ドルに達すると予測され、予測期間の2025年から2033ねんのCAGRは10.6%で成長します。

心房細動とは、心房として知られる心臓の上部の部屋で電気インパルスが乱れ、心拍が速くなったり不規則になったりする状態のことです。この不整脈は、動悸、めまい、疲労、失神などの症状を引き起こすことがあります。心房細動は、高齢者や高血圧、糖尿病、肥満などの基礎疾患を持つ人に特に多くみられます。

世界の心房細動市場は、不規則でしばしば速い心拍を特徴とする不整脈の一種である心房細動（AFib）の診断、治療、管理に特化した経済セクターを包括しています。心房細動は、脳卒中や心不全のリスクを高めるなど、深刻な合併症を引き起こす可能性があり、効果的な治療が不可欠です。これらの要因が、世界の心房細動市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

医療技術の進歩

世界の心房細動（AFib）市場は、医療技術の進歩により、この一般的な不整脈の診断、治療、管理が大きく変化しています。これらの技術革新は、患者の予後を改善するだけでなく、処置の効率を向上させ、ヘルスケアプロバイダーと患者双方にとって治療の選択肢を広げるものです。

この革新的な技術は、従来の加熱または冷却方法とは異なり、マイクロパルスの電気を利用して心臓組織に標的病変を形成するものです。今回のFARAPULSEシステムの承認は、PFAがいかに心房細動治療に精密なアプローチを提供し、肺静脈を効果的に分離して合併症を最小限に抑えることで、より迅速で安全な手技と成功率の向上につながるかを例証するものです。3Dマッピングシステムなどの高度なマッピング技術の統合は、カテーテルアブレーション手技に革命をもたらしました。これらのシステムは、心臓の電気的活動をリアルタイムで可視化し、電気生理学者が心房細動の原因となっている部位を正確に特定し、ターゲットとすることを可能にしています。

心電図機能を備えたスマートウォッチは、継続的な心拍モニタリングのための貴重なツールとして登場しました。アップルウォッチやその他のウェアラブル端末は、心房細動のエピソードをリアルタイムで追跡できるため、従来の心電図（EKG）だけに頼ることなく早期診断が可能になります。AIはアブレーション手技中の信号解析を強化するためにますます活用され、臨床医が不整脈の誘因をより効率的に特定するのに役立っています。過去の心房細動症例から得られた複雑なデータセットを解析することで、AIは介入が必要な部位をピンポイントで特定し、持続性心房細動の治療成功率を高める可能性があります。

さらに、業界の主要企業は、この世界の心房細動市場の成長を後押しする革新的な製品を発表しています。例えば、2024年10月、Johnson &Johnson MedTechは、心房細動（AFib）治療における重要な技術革新を象徴するVARIPULSEプラットフォームを欧州中の病院に導入しました。この革新的なプラットフォームはパルスフィールドアブレーション（PFA）技術を採用しており、薬剤抵抗性の発作性心房細動に苦しむ患者に対して、より安全で効果的なソリューションを提供します。

また、2023年8月、GE HealthCareはCardioVisio for Atrial Fibrillation（AFib）の発売を発表しました。この革新的なデジタルツールは、臨床医が疾患の進行に関連する包括的で縦断的なデータを視覚化することを支援することを目的としています。この革新的なツールは、複数のデータソースからの情報を統合し、臨床上の意思決定を強化し、最新の心房細動ガイドラインに沿ったエビデンスに基づく診療をサポートします。これらすべての要因が、世界の心房細動市場に需要をもたらしています。

さらに、低侵襲治療に対する需要の高まりも、心房細動の世界市場拡大に寄与しています。

高い治療費

心房細動（AFib）の世界市場は、主にこの一般的な不整脈の管理に関連する高額な治療費が大きな課題となっています。これらのコストは、患者が必要な治療を受けることを躊躇させ、ヘルスケアシステムに大きな負担を強いることになります。このような高額な治療費がAFib市場にどのような影響を及ぼしているかを説明します。

2024年2月の米国国立生物工学情報センター（NCBI）の調査データによると、AF患者の年間増加費用は、患者1人当たり1万2,789米ドル+-16万1,749米ドルと推定されます。このヘルスケアコストの大幅な増加は、主に、医療機関への受診率の上昇、心房細動に関連する臨床上の有害事象、心房細動に関連する特定の介入の必要性など、いくつかの重要な要因によるものです。

心房細動患者は、そうでない患者に比べ、一般的に頻繁にヘルスケアを受ける必要があります。これには、入院と外来の両方が含まれ、全体的な医療費の増加につながります。例えば、持続性心房細動（PeAF）の患者は、入院率が高く、病状が複雑であるため、医療費が最も高くなることが多いです。したがって、上記の要因が心房細動の世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 医療技術の進歩
    • 抑制要因
      • 治療費の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 治療タイプ別

  • 薬物治療
    • 抗不整脈薬
    • アミオダロン
    • ドロネダロン
    • ドフェチリド
    • ソタロール
    • フレカイニド
    • プロパフェノン
    • ジゴキシン
    • 抗凝固薬
    • ワルファリン
    • ダビガトラン
    • リバロキサバン
    • アピキサバン
    • エドキサバン
    • 非ジヒドロピリジン系カルシウムチャネル遮断薬
    • ジルチアゼム
    • ベラパミル
    • ベータ遮断薬
    • メトプロロール
    • カルベジロール
  • その他
  • 非薬物治療
    • カテーテルアブレーション
    • 迷路手術
    • 電気的除細動
    • その他

第7章 エンドユーザー別

  • 病院・専門クリニック
  • 外来手術センター
  • その他

第8章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第9章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第10章 企業プロファイル

  • AdvaCare Pharma
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Glenmark Pharmaceuticals Inc.
  • GSK plc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • DAIICHI SANKYO COMPANY, LIMITED.
  • AstraZeneca
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Medtronic
  • Abbott.

第11章 付録

目次
Product Code: PH446

The global atrial fibrillation market reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033.

Atrial fibrillation is a condition in which the heart's upper chambers, known as the atria, experience chaotic electrical impulses, resulting in a fast and irregular heartbeat. This irregularity can cause symptoms such as palpitations, dizziness, fatigue, and fainting. AFib is particularly common among older adults and individuals with underlying health issues such as hypertension, diabetes, and obesity.

The global atrial fibrillation market encompasses the economic sector dedicated to the diagnosis, treatment, and management of atrial fibrillation (AFib), a prevalent type of arrhythmia characterized by irregular and often rapid heartbeats. AFib can lead to serious complications, including an increased risk of stroke and heart failure, making effective treatment essential. These factors have driven the global atrial fibrillation market expansion.

Market Dynamics: Drivers & Restraints

Advances in Medical Technology

The global atrial fibrillation (AFib) market is significantly driven by advances in medical technology, which have transformed the diagnosis, treatment, and management of this prevalent arrhythmia. These innovations not only enhance patient outcomes but also improve procedural efficiencies and expand treatment options for healthcare providers and patients alike.

This innovative technique utilizes micro pulses of electricity to create targeted lesions in cardiac tissue, as opposed to traditional heat or cold methods. The recent approval of the FARAPULSE system exemplifies how PFA provides a more precise approach to AFib treatment, leading to faster, safer procedures and improved success rates by effectively isolating the pulmonary veins and minimizing complications. The integration of advanced mapping technologies, such as 3D mapping systems, has revolutionized catheter ablation procedures. These systems offer real-time visualization of the heart's electrical activity, enabling electrophysiologists to accurately identify and target areas responsible for AFib.

Smartwatches equipped with ECG capabilities have emerged as valuable tools for continuous heart rhythm monitoring. Devices like the Apple Watch and other wearables allow for real-time tracking of AFib episodes, facilitating early diagnosis without relying solely on traditional electrocardiograms (EKGs). AI is increasingly being utilized to enhance signal analysis during ablation procedures, helping clinicians identify arrhythmia triggers more efficiently. By analyzing complex datasets from previous AFib cases, AI can assist in pinpointing areas that require intervention, potentially increasing the success rates of treating persistent AFib.

Furthermore, key players in the industry have innovative launches that would drive this global atrial fibrillation market growth. For instance, in October 2024, Johnson & Johnson MedTech introduced the VARIPULSE Platform in hospitals across Europe, representing a significant innovation in the treatment of atrial fibrillation (AFib). This innovative platform employs pulsed field ablation (PFA) technology, offering a safer and more effective solution for patients suffering from drug-refractory paroxysmal AFib.

Also, in August 2023, GE HealthCare announced the launch of CardioVisio for Atrial Fibrillation (AFib), an innovative digital tool aimed at assisting clinicians in visualizing comprehensive, longitudinal data related to disease progression. This innovative tool integrates information from multiple data sources to enhance clinical decision-making and support evidence-based practices aligned with the latest AFib guidelines. All these factors demand the global atrial fibrillation market.

Moreover, the growing demand for minimally invasive procedures contributes to the global atrial fibrillation market expansion.

High Costs of Treatment

The global atrial fibrillation (AFib) market faces significant challenges primarily due to the high costs of treatment associated with managing this common arrhythmia. These costs can deter patients from seeking necessary care and place a substantial burden on healthcare systems. Here's an explanation of how these high treatment costs impact the AFib market.

According to the National Center for Biotechnology Information (NCBI) research data in February 2024, the incremental annualized cost for patients with atrial fibrillation (AF) is estimated at $12,789 +- $161,749 per patient. This significant increase in healthcare costs is primarily driven by several key factors, including heightened rates of healthcare encounters, adverse clinical events associated with AF, and the need for specific AF-related interventions.

Patients with AF typically require more frequent healthcare visits compared to those without the condition. This includes both inpatient and outpatient visits, which lead to higher overall medical expenses. For instance, individuals with persistent atrial fibrillation (PeAF) often incur the highest costs due to increased hospitalization rates and the complexity of their condition. Thus, the above factors could be limiting the global atrial fibrillation market's potential growth.

Segment Analysis

The global atrial fibrillation market is segmented based on treatment type, end-user, and region.

Treatment Type:

The pharmacological treatment segment is expected to dominate the global atrial fibrillation market share

The pharmacological treatment segment holds a major portion of the global atrial fibrillation market share and is expected to continue to hold a significant portion of the global atrial fibrillation market share during the forecast period.

The pharmacological treatment segment for atrial fibrillation (AFib) is essential for managing this common heart condition and preventing its serious complications, particularly strokes. This segment is primarily divided into two main categories including anti-arrhythmic drugs and anticoagulant drugs. Anti-arrhythmic medications are designed to control heart rhythm and alleviate symptoms associated with AFib. They function by normalizing the heart's electrical activity or reducing the frequency of arrhythmias. These medications stabilize the heart's electrical activity by affecting ion channels involved in cardiac conduction, helping restore a normal rhythm and potentially reducing episodes of AFib.

Commonly used anti-arrhythmic drugs include amiodarone, sotalol, and flecainide. The choice of drug often depends on the patient's specific condition, including the type of AFib (paroxysmal, persistent, or permanent) and any underlying health issues.

Anticoagulants play a crucial role in preventing blood clots, which can lead to strokes-a significant risk associated with AFib. Warfarin has been the traditional anticoagulant for many years. While effective, it requires regular monitoring of blood levels (International Normalized Ratio, INR) to ensure therapeutic effectiveness and minimize the risk of bleeding. Many patients find managing warfarin challenging due to its complexity and dietary restrictions. More recently, NOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban have emerged as preferred alternatives to warfarin. These newer agents do not require routine monitoring and have fewer dietary restrictions, making them more convenient for patients.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this segment's growth in the global atrial fibrillation market. For instance, in December 2024, the FDA approved Rapiblyk (landiolol), a new medication specifically designed for the rapid management of irregular heartbeats in critically ill hospitalized patients experiencing severe supraventricular tachycardia (SVT), which includes conditions such as atrial fibrillation and atrial flutter. This approval represents a significant advancement in treatment options available for patients facing these potentially life-threatening arrhythmias. These factors have solidified the segment's position in the global atrial fibrillation market.

Geographical Analysis

North America is expected to hold a significant position in the global atrial fibrillation market share

North America holds a substantial position in the global atrial fibrillation market and is expected to hold most of the market share. The rising incidence of atrial fibrillation is a major driver of market growth. In the United States, Atrial fibrillation (AFib) is recognized as the most common form of irregular heartbeat, and it is projected that by 2030, around 12.1 million adults in the United States will be affected by this condition, with projections suggesting this number could reach 12.1 million by 2030. This escalating prevalence emphasizes the need for effective treatment options.

The aging demographic significantly contributes to the higher prevalence of AFib. As the population ages, there is an increased likelihood of developing cardiovascular conditions, leading to a greater demand for AFib treatments. Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options and attracting more patients toward specialized care. These advancements not only improve clinical outcomes but also increase patient preference for minimally invasive procedures.

Furthermore, a major number of key players' presence, well-advanced healthcare infrastructure, key initiatives & product approvals would drive this global atrial fibrillation market growth. For instance, in April 2024, the American Heart Association (AHA) initiated a new program aimed at involving pharmacists in the management of patients with atrial fibrillation (AFib), a prevalent heart condition affecting millions. This initiative is part of the AHA's broader Four Fs of Atrial Fibrillation campaign, which seeks to address specific patient health concerns that can impede effective anticoagulant therapy.

Also, in February 2023, Abbott announced two significant regulatory approvals as part of its expanding range of electrophysiology products in the global market. The TactiFlex Ablation Catheter, Sensor Enabled, recognized as the world's only ablation catheter with a flexible tip and contact force sensing technology, has received the CE Mark for use in treating patients with abnormal heart rhythms, including atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as a dominant force in the global atrial fibrillation market.

Asia Pacific is growing at the fastest pace in the global atrial fibrillation market share

Asia Pacific holds the fastest pace in the global atrial fibrillation market and is expected to hold most of the market share, fuelled by various factors that reflect the increasing prevalence of this condition and advancements in healthcare. Currently, more than 16 million people in the Asia Pacific region are affected by atrial fibrillation, with projections indicating this number could rise to 72 million by 2050. This escalating prevalence underscores the urgent need for effective treatment options.

The rising incidence of atrial fibrillation is a primary driver of market growth. The significant increase in AFib cases necessitates enhanced diagnostic and treatment options across the region. The aging demographic in Asia Pacific countries, particularly in nations like China and India, significantly contributes to the higher prevalence of AFib. As older adults are at a greater risk for cardiovascular diseases, this trend leads to increased demand for AFib treatments.

Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options for AFib patients. These advancements not only improve patient outcomes but also increase the preference for minimally invasive procedures. Increased healthcare spending in many Asia Pacific countries supports the adoption of advanced treatment options for AFib. This financial commitment allows for better access to medications, devices, and specialized care facilities.

Furthermore, key player's strategies such as partnerships & collaborations and innovative product launches & approvals would drive this global atrial fibrillation market growth. For instance, in May 2024, OMRON Healthcare India partnered with AliveCor India, a leader in personal electrocardiogram (ECG) technology, to enhance its cardiovascular health monitoring solutions, particularly focusing on atrial fibrillation (AFib). This collaboration is significant as it allows OMRON, which is primarily known for its blood pressure monitoring devices, to expand into the realm of AI-based handheld ECG technology.

Also, in May 2024, Medtronic announced that its PulseSelect pulsed field ablation (PFA) system has received regulatory approval in Japan, significantly expanding the availability of this innovative technology for treating patients with paroxysmal and persistent atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as the fastest-growing force in the global atrial fibrillation market.

Competitive Landscape

The major global players in the atrial fibrillation market include AdvaCare Pharma, Sanofi, Pfizer Inc. Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., GSK plc., Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, DAIICHI SANKYO COMPANY, LIMITED., AstraZeneca, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and Abbott. among others.

Key Developments

  • In November 2024, Johnson & Johnson MedTech announced that the U.S. Food and Drug Administration (FDA) has approved its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib). This approval signifies a major advancement in cardiac arrhythmia treatment, particularly for patients who do not respond to standard drug therapies.
  • In May 2024, Saint Luke's Mid-America Heart Institute launched a comprehensive digital health program in partnership with Story Health to support patients diagnosed with atrial fibrillation (AFib) or those at risk of developing the condition. This initiative aims to enhance patient care by providing continuous support and engagement beyond traditional clinic visits.
  • In March 2024, Asheville's Mission Hospital announced that it is the first facility in North Carolina to implement a new ablation strategy for treating atrial fibrillation (AFib), the most common type of arrhythmia, which affects approximately seven million Americans. This innovative procedure utilizes the FARAPULSE PFA System, a state-of-the-art technology that enhances both the safety and effectiveness of AFib treatment.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global atrial fibrillation market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End-User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advances in Medical Technology
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Pharmacological Treatment*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Anti-arrhythmic Drugs
    • 6.2.4. Amiodarone
    • 6.2.5. Dronedarone
    • 6.2.6. Dofetilide
    • 6.2.7. Sotalol
    • 6.2.8. Flecainide
    • 6.2.9. Propafenone
    • 6.2.10. Digoxin
    • 6.2.11. Anticoagulant Drugs
    • 6.2.12. Warfarin
    • 6.2.13. Dabigatran
    • 6.2.14. Rivaroxaban
    • 6.2.15. Apixaban
    • 6.2.16. Edoxaban
    • 6.2.17. Non-Dihydropyridine Calcium Channel Blockers
    • 6.2.18. Diltiazem
    • 6.2.19. Verapamil
    • 6.2.20. Beta-Blockers
    • 6.2.21. Metoprolol
    • 6.2.22. Carvedilol
  • 6.3. Others
  • 6.4. Non-Pharmacological Treatment
    • 6.4.1. Catheter Ablation
    • 6.4.2. Maze Surgery
    • 6.4.3. Electric Cardioversion
    • 6.4.4. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals & Specialty Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Spain
      • 8.3.5.5. Italy
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. South Korea
      • 8.5.5.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 10.1. AdvaCare Pharma*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Sanofi
  • 10.3. Pfizer Inc.
  • 10.4. Teva Pharmaceuticals USA, Inc.
  • 10.5. Glenmark Pharmaceuticals Inc.
  • 10.6. GSK plc.
  • 10.7. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.8. Bayer AG
  • 10.9. DAIICHI SANKYO COMPANY, LIMITED.
  • 10.10. AstraZeneca
  • 10.11. Johnson & Johnson
  • 10.12. Boston Scientific Corporation
  • 10.13. Medtronic
  • 10.14. Abbott.

LIST NOT EXHAUSTIVE

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us